✦ LIBER ✦

Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

✍ Scribed by S.J. Hadziyannis; H. Cheinquer; T. Morgan; M. Diago; D.M. Jensen; H. Sette Jr.; G. Ramadori; H.C. Bodenheimer; P. Marcellin; S.-D. Lee; P.J. Roberts; A.M. Ackrill

Book ID: 118564917
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 147 KB
Volume: 36
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(02)80001-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re-treatment of interferon (IFN) plus ri

Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study

✍ S. Brillanti; A. Mangia; L. Cimino; A. Civolani; F. Fatuzzo; L. Fenoglio; M. Lev 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Pegylated (40kDa) interferon alfa-2a (PE

Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

✍ Michael W. Fried; Mitchell L. Shiffman; Rejender K. Reddy; Coleman Smith; George 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 196 KB

95 Peginterferon alfa-2A (40KD) (PEGASYS

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

✍ P. Marcellin; G.K.K. Lau; F. Bonino; P. Farci; S. Hadziyannis; R. Jin; Z.-M. Lu; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 64 KB

1181 A phase III, partially double-blind

1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B

✍ MARCELLIN, P; LAU, G; BONINO, F; FARCI, P; HADZIYANNIS, S; JIN, R; LU, Z; PIRATV 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

15 TELAPREVIR (TVR) q8h OR q12h COMBINED

15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208

✍ M. Colombo; M.G. Rumi; G. Carosi; M. Puoti; P. Marcellin; X. Forns; T. Göser; P. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

40 kDa peginterferon alfa-2A (PEGASYS®):

40 kDa peginterferon alfa-2A (PEGASYS®): efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B: Graham E Cooksley, Royal Brisbane Hospital, Herston, Queensland Australia; Teerha Piratvisuth, Songklanakarin Hospital, Songkla Thailand; Yuan-Jen Wang, Teipei Veterans General Hospital, Taipei Taiwan; Varocha Mahachai, Chulalongkorn Hospital, Bangkok Thailand; You-Chen Chao, Tri Service General Hosptital, Taipei Taiwan; Tawesak Tanwandee, Siriraj Hospital, Bangkok Thailand; Anuchit Chutaputti, Pramongkutklao Hospital, Bangkok Thailand; Wen Yu Chang, Kaohsiung University Hospital, Kaohsiung Taiwan; Friederike E Zahm, Hoffmann-La Roche Basel Switzerland; Nigel Pluck, Roche Products Ltd, Welwyn Uk

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB